---
title: "Star Lake Science adjusts corn futures hedging transactions and increases options contracts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257358870.md"
description: "Star Lake Science approved the proposal to adjust corn futures hedging transactions at the 13th meeting of the 11th Board of Directors, increasing trading of on-exchange and off-exchange corn options contracts. The trading period is until April 19, 2026, with a maximum margin requirement of 50 million yuan and a maximum contract value of 500 million yuan, funded by its own capital. This move aims to control raw material price risks but still faces market and liquidity risks, and corresponding risk control measures have been established"
datetime: "2025-09-15T11:41:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257358870.md)
  - [en](https://longbridge.com/en/news/257358870.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257358870.md)
generator: "portal-rs"
---

# Star Lake Science adjusts corn futures hedging transactions and increases options contracts

On September 15, 2025, the 13th meeting of the 11th Board of Directors of Guangdong Zhaoqing Star Lake Biotechnology Co., Ltd. reviewed and approved the proposal on adjusting matters related to corn futures hedging transactions. To enhance flexibility, the company will add on-exchange and off-exchange corn options contract trading based on the standard corn futures contracts on domestic futures exchanges, while the other contents of the original proposal remain unchanged, with the trading period extending to April 19, 2026. The maximum margin required for trading is 50 million yuan, corresponding to a maximum contract value of 500 million yuan, funded by the company's own funds. The company's hedging transactions aim to control raw material price risks; however, it may still face market, liquidity, and other risks, and risk control measures have been established

### Related Stocks

- [600866.CN](https://longbridge.com/en/quote/600866.CN.md)

## Related News & Research

- [Biohit says scientific review backs serum biomarker triage to target endoscopy for gastric cancer risk](https://longbridge.com/en/news/297887371.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)
- [Cleo Diagnostics to Commence Analytical Validation of Pre-Surgical Ovarian Cancer Blood Test](https://longbridge.com/en/news/297848437.md)
- [NeuroThera Labs seeks FDA orphan drug status for adult Tourette treatment SCI-110](https://longbridge.com/en/news/297783543.md)
- [07:15 ETTranspire Bio to Participate in Upcoming Healthcare Investor Conferences During September](https://longbridge.com/en/news/297775966.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**